This was the stock's third consecutive day of gains.

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” third ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $408.18, denoting a +0.72% change from the preceding trading day.

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today. The company’s ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a ...

Equities researchers at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Vertex Pharmaceuticals ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the ...

Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $408.18 which represents a slight increase of $2.91 or 0.72% from the prior close of $405.27. The stock opened at $401.53 ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $408.18, moving +0.72% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.1%.